drug-information.ru |
|Dipyridamole tablets |
Drugs search, click the first letter of a drug name: | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9 Home DipyridamoleGeneric Name: Dipyridamole USP Dosage Form: Tablets Prescribing Information Dipyridamole DescriptionDipyridamole USP is a platelet inhibitor chemically described as 2,2",2",2""-[(4,8-Dipiperidinopyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]-tetraethanol. It has the following structural formula: Dipyridamole is an odorless yellow crystalline powder, having a bitter taste. It is soluble in dilute acids, methanol and chloroform, and practically insoluble in water. Dipyridamole USP tablets for oral administration contain: Active Ingredient TABLETS 25 mg, 50 mg, and 75 mg: Dipyridamole USP 25 mg, 50 mg and 75 mg, respectively. Inactive Ingredients TABLETS 25 mg, 50 mg, and 75 mg: corn starch, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, polyethylene glycol, povidone, and titanium dioxide. Dipyridamole - Clinical PharmacologyIt is believed that platelet reactivity and interaction with prosthetic cardiac valve surfaces, resulting in abnormally shortened platelet survival time, is a significant factor in thromboembolic complications occurring in connection with prosthetic heart valve replacement. Dipyridamole USP tablets have been found to lengthen abnormally shortened platelet survival time in a dose-dependent manner. In three randomized controlled clinical trials involving 854 patients who had undergone surgical placement of a prosthetic heart valve, Dipyridamole USP tablets, in combination with warfarin, decreased the incidence of postoperative thromboembolic events by 62 to 91 % compared to warfarin treatment alone. The incidence of thromboembolic events in patients receiving the combination of Dipyridamole USP tablets and warfarin ranged from 1.2 to 1.8%. In three additional studies involving 392 patients taking Dipyridamole USP tablets and coumarin-like anticoagulants, the incidence of thromboembolic events ranged from 2.3 to 6.9%. In these trials, the coumarin anticoagulant was begun between 24 hours and 4 days postoperatively, and the Dipyridamole USP tablets were begun between 24 hours and 10 days postoperatively. The length of follow-up in these trials varied from 1 to 2 years. Dipyridamole USP tablets do not influence prothrombin time or activity measurements when administered with warfarin. Mechanism of ActionDipyridamole inhibits the uptake of adenosine into platelets, endothelial cells and erythrocytes in vitro and in vivo; the inhibition occurs in a dose-dependent manner at therapeutic concentrations (0.5-1.9 µg/mL). This inhibition results in an increase in local concentrations of adenosine which acts on the platelet A2-receptor thereby stimulating platelet adenylate cyclase and increasing platelet cyclic-3",5"-adenosine monophosphate (cAMP) levels. Via this mechanism, platelet aggregation is inhibited in response to various stimuli such as platelet activating factor (PAF), collagen and adenosine diphosphate (ADP). Dipyridamole inhibits phosphodiesterase (PDE) in various tissues. While the inhibition of cAMP-PDE is weak, therapeutic levels of Dipyridamole inhibit cyclic-3",5"-guanosine monophosphate-PDE (cGMP-PDE), thereby augmenting the increase in cGMP produced by EDRF (endothelium-derived relaxing factor, now identified as nitric oxide). HemodynamicsIn dogs intraduodenal doses of Dipyridamole of 0.5 to 4.0 mg/kg produced dose-related decreases in systemic and coronary vascular resistance leading to decreases in systemic blood pressure and increases in coronary blood flow. Onset of action was in about 24 minutes and effects persisted for about 3 hours. Similar effects were observed following IV Dipyridamole USP in doses ranging from 0.025 to 2.0 mg/kg. In man the same qualitative hemodynamic effects have been observed. However, acute intravenous administration of Dipyridamole USP may worsen regional myocardial perfusion distal to partial occlusion of coronary arteries. Pharmacokinetics and MetabolismFollowing an oral dose of Dipyridamole USP tablets, the average time to peak concentration is about 75 minutes. The decline in plasma concentration following a dose of Dipyridamole USP tablets fits a two-compartment model. The alpha half-life (the initial decline following peak concentration) is approximately 40 minutes. The beta half-life (the terminal decline in plasma concentration) is approximately 10 hours. Dipyridamole is highly bound to plasma proteins. It is metabolized in the liver where it is conjugated as a glucuronide and excreted with the bile. Indications and Usage for DipyridamoleDipyridamole USP tablets are indicated as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement. ContraindicationsHypersensitivity to Dipyridamole and any of the other components. PrecautionsGeneralCoronary Artery Disease: Dipyridamole has a vasodilatory effect and should be used with caution in patients with severe coronary artery disease (e.g., unstable angina or recently sustained myocardial infarction). Chest pain may be aggravated in patients with underlying coronary artery disease who are receiving Dipyridamole. Hepatic Insufficiency: Elevations of hepatic enzymes and hepatic failure have been reported in association with Dipyridamole administration. Hypotension: Dipyridamole should be used with caution in patients with hypotension since it can produce peripheral vasodilation. Laboratory TestsDipyridamole has been associated with elevated hepatic enzymes. Drug InteractionsNo pharmacokinetic drug-drug interaction studies were conducted with Dipyridamole USP Tablets. The following information was obtained from the literature. Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary. Cholinesterase Inhibitors: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis. Carcinogenesis, Mutagenesis, Impairment of FertilityIn studies in which Dipyridamole was administered in the feed to mice (up to 111 weeks in males and females) and rats (up to 128 weeks in males and up to 142 weeks in females), there was no evidence of drug-related carcinogenesis. The highest dose administered in these studies (75 mg/kg/day) was, on a mg/m2 basis, about equivalent to the maximum recommended daily human oral dose (MRHD) in mice and about twice the MRHD in rats. Mutagenicity tests of Dipyridamole with bacterial and mammalian cell systems were negative. There was no evidence of impaired fertility when Dipyridamole was administered to male and female rats at oral doses up to 500 mg/kg/day (about 12 times the MRHD on a mg/m2 basis). A significant reduction in number of corpora lutea with consequent reduction in implantations and live fetuses was, however, observed at 1250 mg/kg (more than 30 times the MRHD on a mg/m2 basis). PregnancyTeratogenic Effects: PREGNANCY CATEGORY B Nursing MothersAs Dipyridamole is excreted in human milk, caution should be exercised when Dipyridamole USP tablets are administered to a nursing woman. Pediatric UseSafety and effectiveness in the pediatric population below the age of 12 years have not been established. Adverse ReactionsAdverse reactions at therapeutic doses are usually minimal and transient. On long-term use of Dipyridamole USP tablets initial side effects usually disappear. The following reactions in Table 1 were reported in two heart valve replacement trials comparing Dipyridamole USP tablets and warfarin therapy to either warfarin alone or warfarin and placebo: Table 1: Adverse Reactions Reported in 2 Heart Valve Replacement Trials
Other reactions from uncontrolled studies include diarrhea, vomiting, flushing and pruritus. In addition, angina pectoris has been reported rarely and there have been rare reports of liver dysfunction. On those uncommon occasions when adverse reactions have been persistent or intolerable, they have ceased on withdrawal of the medication. When Dipyridamole USP tablets were administered concomitantly with warfarin, bleeding was no greater in frequency or severity than that observed when warfarin was administered alone. In rare cases, increased bleeding during or after surgery has been observed. In post-marketing reporting experience, there have been rare reports of hypersensitivity reactions (such as rash, urticaria, severe bronchospasm, and angioedema), larynx edema, fatigue, malaise, myalgia, arthritis, nausea, dyspepsia, paresthesia, hepatitis, thrombocytopenia, alopecia, cholelithiasis, hypotension, palpitation, and tachycardia. OverdosageIn case of real or suspected overdose, seek medical attention or contact a Poison Control Center immediately. Careful medical management is essential. Based upon the known hemodynamic effects of Dipyridamole, symptoms such as warm feeling, flushes, sweating, restlessness, feeling of weakness and dizziness may occur. A drop in blood pressure and tachycardia might also be observed. Symptomatic treatment is recommended, possibly including a vasopressor drug. Gastric lavage should be considered. Administration of xanthine derivatives (e.g., aminophylline) may reverse the hemodynamic effects of Dipyridamole overdose. Since Dipyridamole is highly protein bound, dialysis is not likely to be of benefit. Dipyridamole Dosage and AdministrationAdjunctive Use in Prophylaxis of Thromboembolism after Cardiac Valve Replacement. How is Dipyridamole SuppliedDipyridamole tablets, USP, are available as round, white, film-coated tablets of 25 mg, 50 mg, and 75 mg coded 81/SL, 82/SL, and 83/SL, respectively. They are available in bottles of 100 tablets as indicated below: They are available in bottles of 1000 tablets as indicated below: STORE AT 25°C (77°F); EXCURSIONS PERMITTED TO 15-30°C (59°-86°F) [SEE USP CONTROLLED ROOM TEMPERATURE]. KEEP OUT OF REACH OF CHILDREN. Rx only Manufactured for: Rising Pharmaceuticals, Inc., Allendale, NJ 07401 USA Manufactured by: Murty Pharmaceuticals, Inc., Lexington, KY 40509 USA Rev. 00 (12/06/05) P112-00
Revised: 02/2007 Where can I get more information about Dipyridamole tablets ? We recommend to use www.Drugs.com Typical mistypes for Dipyridamole tablets sipyridamole tablets, xipyridamole tablets, cipyridamole tablets, fipyridamole tablets, ripyridamole tablets, eipyridamole tablets, dupyridamole tablets, djpyridamole tablets, dkpyridamole tablets, dopyridamole tablets, d9pyridamole tablets, d8pyridamole tablets, dioyridamole tablets, dilyridamole tablets, di-yridamole tablets, di0yridamole tablets, diptridamole tablets, dipgridamole tablets, diphridamole tablets, dipuridamole tablets, dip7ridamole tablets, dip6ridamole tablets, dipyeidamole tablets, dipydidamole tablets, dipyfidamole tablets, dipytidamole tablets, dipy5idamole tablets, dipy4idamole tablets, dipyrudamole tablets, dipyrjdamole tablets, dipyrkdamole tablets, dipyrodamole tablets, dipyr9damole tablets, dipyr8damole tablets, dipyrisamole tablets, dipyrixamole tablets, dipyricamole tablets, dipyrifamole tablets, dipyriramole tablets, dipyrieamole tablets, dipyridzmole tablets, dipyridsmole tablets, dipyridwmole tablets, dipyridqmole tablets, dipyridanole tablets, dipyridakole tablets, dipyridajole tablets, dipyridamile tablets, dipyridamkle tablets, dipyridamlle tablets, dipyridample tablets, dipyridam0le tablets, dipyridam9le tablets, dipyridamoke tablets, dipyridamope tablets, dipyridamooe tablets, dipyridamolw tablets, dipyridamols tablets, dipyridamold tablets, dipyridamolr tablets, dipyridamol4 tablets, dipyridamol3 tablets, dipyridamole rablets, dipyridamole fablets, dipyridamole gablets, dipyridamole yablets, dipyridamole 6ablets, dipyridamole 5ablets, dipyridamole tzblets, dipyridamole tsblets, dipyridamole twblets, dipyridamole tqblets, dipyridamole tavlets, dipyridamole tanlets, dipyridamole tahlets, dipyridamole taglets, dipyridamole tabkets, dipyridamole tabpets, dipyridamole taboets, dipyridamole tablwts, dipyridamole tablsts, dipyridamole tabldts, dipyridamole tablrts, dipyridamole tabl4ts, dipyridamole tabl3ts, dipyridamole tablers, dipyridamole tablefs, dipyridamole tablegs, dipyridamole tableys, dipyridamole table6s, dipyridamole table5s, dipyridamole tableta, dipyridamole tabletz, dipyridamole tabletx, dipyridamole tabletd, dipyridamole tablete, dipyridamole tabletw, ipyridamole tablets, dpyridamole tablets, diyridamole tablets, dipridamole tablets, dipyidamole tablets, dipyrdamole tablets, dipyriamole tablets, dipyridmole tablets, dipyridaole tablets, dipyridamle tablets, dipyridamoe tablets, dipyridamol tablets, dipyridamoletablets, dipyridamole ablets, dipyridamole tblets, dipyridamole talets, dipyridamole tabets, dipyridamole tablts, dipyridamole tables, dipyridamole tablet, idpyridamole tablets, dpiyridamole tablets, diypridamole tablets, dipryidamole tablets, dipyirdamole tablets, dipyrdiamole tablets, dipyriadmole tablets, dipyridmaole tablets, dipyridaomle tablets, dipyridamloe tablets, dipyridamoel tablets, dipyridamol etablets, dipyridamolet ablets, dipyridamole atblets, dipyridamole tbalets, dipyridamole talbets, dipyridamole tabelts, dipyridamole tabltes, dipyridamole tablest, ddipyridamole tablets, diipyridamole tablets, dippyridamole tablets, dipyyridamole tablets, dipyrridamole tablets, dipyriidamole tablets, dipyriddamole tablets, dipyridaamole tablets, dipyridammole tablets, dipyridamoole tablets, dipyridamolle tablets, dipyridamolee tablets, dipyridamole tablets, dipyridamole ttablets, dipyridamole taablets, dipyridamole tabblets, dipyridamole tabllets, dipyridamole tableets, dipyridamole tabletts, dipyridamole tabletss, etc.
|